AstraZeneca Chief Executive Pascal Soriot Secures £17.7 Million in 2025 Compensation
The pharmaceutical giant AstraZeneca has disclosed in its latest annual report that Chief Executive Officer Pascal Soriot received a total pay package of £17.7 million for the year 2025. This represents a significant increase of 6.4% from his £16.6 million compensation in the previous year, 2024.
Breakdown of the 2025 Pay Package
The detailed report reveals that Mr. Soriot's remuneration was composed of several key elements. He was awarded an annual bonus of £4.3 million, alongside long-term share awards valued at £11.6 million. These substantial bonuses and share incentives contributed to the overall lift in his total earnings for the year.
This pay rise comes at a time when AstraZeneca has demonstrated robust financial performance. The company reported a remarkable 40% leap in full-year earnings, with its share price also climbing higher over the past twelve months. Earlier in February 2026, the FTSE 100-listed firm announced pre-tax profits of $12.4 billion (£9.2 billion) for 2025, up from $8.69 billion (£6.43 billion) in 2024, driven by a strong 49% surge in the fourth quarter alone.
Potential for Further Increases in 2026
Looking ahead, the annual report indicates that Mr. Soriot could be in line for another substantial pay increase in 2026. If he meets all his performance targets, his maximum possible pay deal could reach £19.6 million. This potential package would include a £4.3 million annual bonus, a £2.1 million share grant, and up to £11.6 million in long-term share awards, in addition to his base salary of £1.6 million.
AstraZeneca expects continued growth in earnings over the coming year, bolstered by strong demand for its cancer treatments. The Anglo-Swedish group is also expanding its presence in key markets such as the United States and China, while investing in the development of increasingly popular weight-loss medications.
Contrast with UK Investment Decisions
Despite these financial successes and executive pay rises, AstraZeneca has scaled back some of its investment plans in the United Kingdom. In 2025, the company cancelled a planned £450 million expansion of its vaccine facility in Speke, near Liverpool. It also abandoned plans for a £200 million investment into research at its Cambridge headquarters, signaling a shift in its strategic focus away from the UK.
Mr. Soriot has consistently been named the highest-paid chief executive of a FTSE 100 firm in recent years. The annual report further highlights that his 2025 pay was 176 times the average salary of an AstraZeneca worker, underscoring the significant disparity between executive and employee compensation within the company.
The disclosure of these figures comes amid ongoing scrutiny of executive pay in the corporate sector, particularly in industries like pharmaceuticals where companies benefit from high demand for essential treatments. AstraZeneca's performance and its leadership rewards will likely continue to be a topic of discussion among investors and stakeholders as the firm navigates future growth challenges and opportunities.
